According to the provider service MedicarePartD.org, this was Medicare's first direct price negotiation with pharmaceutical companies for ten particularly high-spending Part D drugs. According to CMS, the negotiated maximum prices for the ten selected drugs were due to take effect on January 1, 2026. The exact price negotiated for Januvia is not available in the sources reviewed. The Merck Sharp Dohme drug, which is used to treat diabetes, is among the ten drugs whose selection for the first round of negotiations CMS announced on August 29, 2023. About 850,000 Medicare beneficiaries received Januvia in 2023; Medicare's Part D program spent more than $4 billion on it, according to AARP.
New negotiation authority since 2022
According to CMS, the Inflation Reduction Act gives Medicare the ability to negotiate prices directly with manufacturers for certain high-spending drugs from a single source that face no generic or biosimilar competition. The negotiation period was scheduled to run from October 21, 2023, to August 1, 2024, according to the GAO report on the implementation of Medicare pricing rules. CMS said on August 15, 2024, that the negotiation period ended with an agreement on prices for the ten selected drugs. In addition to the negotiation program, the Inflation Reduction Act also requires manufacturers to pay rebates to CMS if the prices of certain Medicare-covered drugs rise faster than inflation, according to GAO. The sources reviewed contain no separate statement from Merck Sharp Dohme on the negotiated price. According to CMS, about 8.8 million of the 54 million people with Medicare Part D coverage received one of the ten selected drugs between January and December 2023, for example to treat heart disease, diabetes, autoimmune diseases or cancer. CMS refers to a separate explanation file for Januvia; according to CMS, the explanations contain redactions to protect confidential company information.

What the new price means for beneficiaries
According to CMS, participating companies must make the negotiated price available to pharmacies, mail-order services and other dispensing entities that provide the drug to eligible people. The ten drugs must also be included on the drug lists of all Medicare Advantage plans with drug coverage and all standalone Part D plans, according to AARP. According to GAO, the negotiated price sets the maximum amount plans may pay pharmacies for the drug, plus dispensing fees; how much individual beneficiaries pay themselves depends on their plan's drug formulary, cost sharing and coverage phase. For most other Part D drugs, plans themselves negotiate prices with manufacturers and payment rates with pharmacies, according to GAO. According to CMS, the price applies as long as the drug remains in the negotiation program; for each subsequent year, the agency publishes an updated price based on the consumer price index. In August 2024, CMS estimated that, had the negotiated prices applied to all ten drugs in 2023, they would have saved Medicare a net $6 billion, or 22 percent; for beneficiaries with Medicare drug coverage, the agency projected $1.5 billion for 2026 under the projected standard benefit design. The $6 billion estimate refers to all ten drugs combined and is a hypothetical comparison for 2023, not a separately reported saving for Januvia.
Januvia compared with selected Medicare drugs
Januvia ranked below Eliquis and Jardiance in total gross spending in 2023: According to the brief dated August 14, 2024, Januvia accounted for $4,091,399,000 in gross Medicare Part D spending, while Eliquis accounted for $18,275,108,000 and Jardiance for $8,840,947,000 in the same year. Together, the ten selected drugs accounted for $56.2 billion in 2023, about 20 percent of total Part D gross spending that year. Part D gross spending on these ten drugs had previously more than doubled from about $20 billion in 2018 to about $46 billion in 2022, an increase of 134 percent, according to the trade publication US Pharmacist. Together with those in the second round of negotiations, the selected drugs had already reached more than $103 billion in gross spending in 2024, over 36 percent of total Part D gross spending and more than 60 percent of all manufacturer rebates, according to the MedPAC report dated February 19, 2026. The discount of 38 to 79 percent from 2023 list prices cited in several sources refers to the ten drugs in the first round of negotiations; in addition, according to the brief, the list price does not reflect actual transaction prices because it does not include rebates and other discounts.
What could influence program spending
The overall effect is uncertain: According to its report dated February 19, 2026, MedPAC expects lower prices at the point of sale for beneficiaries, but also sees both downward and upward pressure on premiums and Medicare subsidies as a result of the shift from rebates to negotiated maximum prices. The commission describes the net effect on overall program spending as uncertain. In its report dated February 28, 2025, MedPAC had already described its findings on effects to date as preliminary, because various changes under the Inflation Reduction Act and subsequent policy changes were likely to interact in ways that would be difficult to disentangle and would need continued monitoring. A modeling study published in Value in Health in March 2026 projected that Medicare Part D net spending on the ten drugs in 2026 would be $23.8 billion with negotiation, compared with $26.1 billion in a scenario without negotiation and without changes to the previous rebate program, a decrease of $2.3 billion, or 8.8 percent, with quantities and net prices adjusted for the expected market entry of generics and biosimilars.
